2023 Fall Conference Exhibit and On-site Guide

Exhibit and On-site Guide #AANFC

Download the AAN Conferences mobile app

Scan to DOWNLOAD app

IT’S NOT ME,

IT’S YOU.

COMMUNICATION MISALIGNMENT AND STRATEGIES TO CLOSE THE MIGRAINE TREATMENT GAP.

WHAT’S INSIDE Meeting Tips............................................................2 Meeting-at-a-glance...............................................4 Pre-conference Schedule........................................6 Fall Conference Schedule........................................7 Exhibit Hall Map.....................................................28 Exhibitor Listing....................................................29 Conference Guidelines and Policies......................36

Share your experience on social media using #AANFC

AAN.com/FCQuickLinks

1

MEETING TIPS Quick Links For handy access to most of the links mentioned below and to download your certificate of attendance, visit AAN.com/FCQuickLinks.

WiFi WiFi is available throughout the conference.

Network: Caesars_Resorts

Audience Response Some programs will seek input from participants in real time. To participate in audience response, visit AAN.cnf.io.

AAN Conferences Mobile App Download the AAN Conferences mobile app at AAN.com/MobileApp and log in with your six-digit AAN ID and password to build your personalized schedule, get notification reminders throughout the conference, see program materials, claim CME, and more. The mobile app seamlessly syncs with the online platform for easy access on any mobile device.

Livestreaming & Session Recordings You can livestream and watch recordings of most sessions on the AAN Conferences mobile app or by visiting AAN.com/FCOnline.

Log in with your six-digit AAN ID and password. Session recordings will be available approximately 24 hours after their originally scheduled time. You can access session recordings through November 13, with your registration. If you upgraded to On Demand, you’ll have access to session recordings in the Online Learning Center (learning.aan.com) from November 14-August 1, 2024. Add Fall Conference On Demand to your registration by emailing us at aanfcsupport@cmrus.com and save up to 55% off through November 13.

2 #AANFC

MEETING TIPS Program Materials Program materials are available online at AAN.com/Materials. Use your six-digit AAN ID and password to log in. Please note that availability of materials is at the discretion of the specific speaker. Not all sessions will have materials.

Claiming CME Credits CME hours can be claimed by completing the program evaluation at AAN.com/CME by November 13, 2023, with Full Registration or by August 1, 2024, if you added On Demand. Transcripts will be available upon evaluation submission. AAN members can also access their transcript via NeuroTracker™ at AAN.com/NeuroTracker.

Meals A light breakfast, lunch, and the exhibit hall reception are included with your registration.

Nursing & Prayer Room A private room for nursing/pumping and/or praying is available for use during the conference. Visit Registration for access.

Exhibit Hall Learn about the latest advancements in products and services enhancing the lives of neurology patients and their care providers.

Use your Exhibit Hall passport to visit a world of exhibitors and enter drawings to win prizes including a Paris Spa Gift Certificate, 2024 AAN membership, and registration to the 2024 AAN Annual Meeting.

Join us for the Exhibit Hall Reception on Friday, October 27, from 4:00 p.m.–5:30 p.m., for the opportunity to enjoy refreshments, network with new and known colleagues, and visit exhibits.

AAN.com/FCQuickLinks

3

MEETING-AT-A-GLANCE THURSDAY, OCTOBER 26

Location: Vendome A

Advanced Practice Provider Pre-conference (separate registration required)

Morning

FRIDAY, OCTOBER 27 Best-of from 2023 Annual Meeting

Practice Management

Leadership University

Neurology Updates

Vendome B

Vendome C

Vendome A

C3 Payvider: Minding the Gap

∆ L1 Leading the Self – Knowing Who You Are and What You Want

C1 Dementia and Neuroimaging

C2 Atypical Parkinsonism

C5 Staffing

∆ L2 Turning Conflict into Collaboration: A Neuroscience-based Tool to Better Lead Yourself and Your Team: Part I

C4 Cerebrovascular Disease and Functional Neurological Disorders

PL1 Neurology Year in Review Plenary Session

Concorde B

∆ Exhibit Hall Lunch

Afternoon

C8 Reducing Administrative Burden

∆ L3 Turning Conflict into Collaboration: A Neuroscience-based Tool to Better Lead Yourself and Your Team: Part II

C7 New Therapies for C6 Neuroophthalmology Migraine and Other and Neurootology Headache Disorders

∆ Exhibit Hall Break

C11 Learning Health Care System

∆ L4 Systems Leadership: Leadership Insights

C9 MS and Autoimmune Neurology

C10 Artificial Intelligence in Clinical Neurology

∆ Exhibit Hall Reception

∆ Industry Therapeutic Update from Eisai: An Option for Intervention in Early Alzheimer’s Disease: MCI Due to AD or Mild AD Dementia

4 #AANFC

MEETING-AT-A-GLANCE SATURDAY, OCTOBER 28 Practice Management

Neurology Updates/ Continuum®

Best-of from 2023 Annual Meeting

Vendome B

Vendome A

Concorde B

Morning

∆ Industry Therapeutic Update from Eli Lilly: It’s Not Me, It’s You. Communication Misalignment and Strategies to Close the Migraine Treatment Gap. C12 Neurocritical Care and Concussion

C14 Artificial Intelligence

C13 Neurologic Conditions in Transgender Patients

∆ Exhibit Hall Break

C17 Building Service Lines

C15 Headache and Epilepsy

C16 Microlearning: Cerebrovascular Disease

Afternoon

∆ Exhibit Hall Lunch

C19 Coding

C18 Continuum Test Your Knowledge: A Multiple-choice Question Review 1

N1 Neuroscience in the Clinic: Myasthenia Gravis: From Pathogenesis to Targeted Therapies

C23 Beyond the Bedside: Integrating APPs

C21 Continuum Test Your Knowledge: A Multiple-choice Question Review 2

C22 Infections of the Nervous System

C20 Anti-amyloid Therapy Boot Camp (Vendome C)

SUNDAY, OCTOBER 29 Best-of from 2023 Annual Meeting

Neurology Updates

Morning

Concorde A

Concorde B

C24 Movement Disorders and Infectious Disease

C25 Epilepsy Therapy Update

C26 Neuromuscular and Autonomic Disorders

C27 Myelin Oligodendrocyte Glycoprotein Antibody Disorders (MOGAD)

∆ Las Vegas Only AAN.com/FCQuickLinks

5

SCHEDULE

THURSDAY, OCTOBER 26

8:00 a.m.–5:30 p.m.

APP: AAN Advanced Practice

Provider Neurology Conference

7.5

THURSDAY, OCTOBER 26

Location: Vendome A Learning Objectives: Participants should become familiar with basic neuroanatomy and issues related to localizing the lesion in neurology with clinical correlations; the application of EMG and EEG in clinical practice, including use and interpretation; and the application and interpretation of the most commonly used imaging strategies for the assessment of the brain and spine, including CT and MRI. In the applied clinical neuropharmacology sessions, participants will develop an understanding of a spectrum of medical management strategies for common clinical topics in neurology, including migraine and other headache disorders, epilepsy, multiple sclerosis, and Alzheimer’s disease.

Lecture/Faculty: 8:00 a.m.–8:15 a.m. » Welcome & Introductions Robert D. Brown, Jr., MD, MPH, FAAN, Rochester, MN Calli Leighann Cook, DNP, FNP-C, FAANP, Atlanta, GA 8:15 a.m.–9:15 a.m. » Localizing the Lesion: Clinical Correlations of Neuroanatomy Part 1: Neuroanatomy Basics and Localizing the Lesion Jaffar Khan, MD, FAAN, Atlanta, GA 9:15 a.m.–9:25 a.m. » Break 9:25 a.m.–10:25 a.m. » Localizing the Lesion: Clinical Correlations of Neuroanatomy Part 2: Applied Neuroanatomy: Clinical Correlation Jaffar Khan, MD, FAAN, Atlanta, GA 10:25 a.m.–10:45 a.m. » Break 10:45 a.m.–11:30 a.m. » Neurodiagnostic Studies: The Use and Interpretation of Neurophysiology Techniques in Clinical Practice: Neurophysiology (EMG) Ruple S. Laughlin, MD, FAAN, Rochester, MN 11:30 a.m.–12:15 p.m. » Neurodiagnostic Studies: The Use and Interpretation of Neurophysiology Techniques in Clinical Practice: Neurophysiology (EEG) Rebecca E. Matthews, MD, Atlanta, GA 12:15 p.m.–1:15 p.m. » Lunch/Networking in Vendome B

6 #AANFC

1:15 p.m.–2:00 p.m. » Neurodiagnostic Studies: The Use and Interpretation of Neuroimaging Techniques in Clinical Practice: Brain Ryan Hakimi, DO, FAAN, Greenville, SC 2:00 p.m.–2:45 p.m. » Neurodiagnostic Studies: The Use and Interpretation of Neuroimaging Techniques in Clinical Practice: Spine Ryan Hakimi, DO, FAAN, Greenville, SC 2:45 p.m.–3:00 p.m. » Break 3:00 p.m.–3:30 p.m. » Applied Neuropharmacology in Clinical Practice: Migraine and Other Headache Disorders Calli Leighann Cook, DNP, FNP-C, FAANP, Atlanta, GA 3:30 p.m.–4:00 p.m. » Applied Neuropharmacology in Clinical Practice: Epilepsy Lucretia Long, CNP, Columbus, OH 4:00 p.m.–4:10 p.m. » Break 4:10 p.m.–4:30 p.m. » Applied Neuropharmacology in Clinical Practice: Multiple Sclerosis Kristi Epstein, NP, Columbus, OH 4:30 p.m.–5:10 p.m. » Applied Neuropharmacology in Clinical Practice: Alzheimer’s Disease Vijay K. Ramanan, MD, PhD, Rochester, MN 5:10 p.m.–5:30 p.m. » Wrap Up and Adjourn Robert D. Brown, Jr., MD, MPH, FAAN, Rochester, MN Calli Leighann Cook, DNP, FNP-C, FAANP, Atlanta, GA

Information is accurate as of October 10, 2023, and is subject to change.

FRIDAY, OCTOBER 27 8:00 a.m.–9:30 a.m.

C1: Neurology Update 1: Dementia and Neuroimaging

1.5

Location: Vendome A

8:45 a.m.–9:15 a.m. » PSP and CBD: From Pathophysiology to Disease-modifying Interventions Miriam M. Sklerov, MD, Chapel Hill, NC 9:15 a.m.–9:25 a.m. » Questions and Answers Miriam M. Sklerov, MD, Chapel Hill, NC 9:25 a.m.–9:30 a.m. » Closing Remarks Alessandra Fanciulli, MD, PhD, Innsbruck, Austria

Learning Objectives: Participants will get an update on the systematic approach for interpretation of neuroimaging studies and new and emerging neuroimaging techniques.

Participants will also identify and explain recent advancements in dementia research and its implications in prevention, diagnosis, and care of patients with cognitive impairment.

C3: Practice Management 1: Payvider: Minding the Gap

Lecture/Faculty:

Location: Vendome B

8:00 a.m.–8:45 a.m. » Unveiling New Horizons and Insights in Dementia Parichita Choudhury, MD, Sun City, AZ 8:45 a.m.–9:30 a.m. » Update on Neuroimaging Joshua P. Klein, MD, PhD, FANA, FAAN, Boston, MA

Learning Objectives: Updated description forthcoming. Please continue to check AAN.com for any updates.

C2 : Atypical Parkinsonism Location: Concorde B

1.5

1.5

Lecture/Faculty:

FRIDAY, OCTOBER 27

8:00 a.m.–9:30 a.m.

8:00 a.m.–9:30 a.m.

8:00 a.m.–9:00 a.m. » Payvider: Minding the Gap Aiesha Ahmed, MD, FAAN, Grand Rapids, MI David A. Evans, MBA, Dallas, TX Kavita Nair, PhD, FAAN, Aurora, CO

Learning Objectives: Participants should become familiar with the features to suspect the diagnosis of atypical Parkinsonian disorders, including MSA, PSP, and CBD. They should be able to discuss the diagnostic work-up based on the most recent diagnostic criteria and formulate therapeutic recommendations for the key motor and non-motor features. They should be also informed about the pathophysiological rationale of disease-modifying approaches currently under development.

Lecture/Faculty: 8:00 a.m.–8:05 a.m. » Introduction Alessandra Fanciulli, MD, PhD, Innsbruck, Austria 8:05 a.m.–8:35 a.m. » Diagnose, Care, and Cure MSA Alessandra Fanciulli, MD, PhD, Innsbruck, Austria 8:35 a.m.–8:45 a.m. » Questions and Answers Alessandra Fanciulli, MD, PhD, Innsbruck, Austria

AAN.com/FCQuickLinks

7

SCHEDULE

FRIDAY, OCTOBER 27

8:00 a.m.–9:30 a.m.

L1: Leading the Self – Knowing Who Are and What You Want

1.5

FRIDAY, OCTOBER 27

Location: Vendome C Learning Objectives: To lead others most effectively, you first need to know how to lead yourself. Where are you going, why are you going there, and what impact do you want to make along the way? The answers to these questions form the foundation to the purpose, the mission, the vision, and the goals that guide your leadership approach and support your own and others’ engagement and success. Participants of this session will continue to build their leadership foundations and create an initial draft of a leadership purpose statement. Participants should also be able to develop a personal mission and vision, outline personal goals, and develop more confidence. This program will not be available within the online platform.

8:00 a.m.–8:05 a.m. » Introductions Mona Bahouth, MD, Baltimore, MD Robin Stubblefield, MA, ACC, Minneapolis, MN 8:05 a.m.–8:20 a.m. » Personal Mission and Vision Mona Bahouth, MD, Baltimore, MD 8:20 a.m.–9:00 a.m. » Interactive Group Work and Discussion Mona Bahouth, MD, Baltimore, MD Robin Stubblefield, MA, ACC, Minneapolis, MN 9:00 a.m.–9:30 a.m. » Questions and Answers Mona Bahouth, MD, Baltimore, MD Robin Stubblefield, MA, ACC, Minneapolis, MN

10:00 a.m.–10:45 a.m. » Cerebrovascular Disease Shadi Yaghi, MD, Barrington, RI 10:45 a.m.–11:30 a.m. » Functional Neurological Disorders Selim R. Benbadis, MD, FAAN, Tampa, FL

10:00 a.m.–11:30 a.m.

C5: Practice Management 2: Staffing

1.5

Location: Vendome B

Lecture/Faculty: 10:00 a.m.–10:30 a.m. » Staffing Ramon L. Rodriguez Cruz, MD, FAAN, Orlando, FL 10:30 a.m.–11:00 a.m. » The Good, the Bad, the Ugly: Lessons and Solutions for Practice Staffing Challenges Lee Williams, Amherst, NY

10:00 a.m.–11:30 a.m.

Cerebrovascular Disease and Functional Neurological Disorders

Lecture/Faculty:

Learning Objectives: Participants will review what has worked and what hasn’t since the pandemic ended; gain and understanding of the balance between recruitment, retention, and turnover and the role culture plays in that balance;and should leave with at least 3-4 practical solutions to consider or try out in their practice setting.

Lecture/Faculty:

C4: Neurology Update 2:

neurology and outside of neurology; review the various psychiatric diagnoses underlying psychogenic symptoms; and understand the basic principles of treatment for psychogenic symptoms. Participants will also get an overview of new indications for intravenous thrombolysis in acute ischemic stroke, learn about advances in mechanical thrombectomy treatment, and discuss updates in secondary stroke prevention.

1.5

Location: Vendome A Learning Objectives: Participants should be able to understand the prevalence and importance of functional neurologic disorders (FND); review the diagnosis of psychogenic seizures as a prototype of FND; review diagnostic methods for psychogenic symptoms commonly seen in

8 #AANFC

Information is accurate as of October 10, 2023, and is subject to change.

FRIDAY, OCTOBER 27 10:00 a.m.–11:30 a.m.

L2 : Turning Conflict into Collaboration: A Neuroscience Based Tool to Better 1.5 Lead Yourself & Your Team Location: Vendome C

Lecture/Faculty: 10:00 a.m.–10:10 a.m. » Introduction & Icebreaker Jeffrey C. McClean, II, MD, FAAN, San Antonio, TX 10:10 a.m.–10:25 a.m. » Introduction to SCARF Ezgi Tiryaki, MD, FAAN, Minneapolis, MN 10:25 a.m.–10:30 a.m. » Case Study & Discussion Jeffrey C. McClean, II, MD, FAAN, San Antonio, TX 10:30 a.m.–10:35 a.m. » Large Group Debrief Jeffrey C. McClean, II, MD, FAAN, San Antonio, TX 10:35 a.m.–10:50 a.m. » Personal Reflection & Large Group Activity Ezgi Tiryaki, MD, FAAN, Minneapolis, MN 10:50 a.m.–11:00 a.m. » Reframing Content Mona Bahouth, MD, Baltimore, MD 11:00 a.m.–11:10 p.m. » Triad Discussions Mona Bahouth, MD, Baltimore, MD 11:10 a.m.–11:15 a.m. » Individual Action Planning Mona Bahouth, MD, Baltimore, MD 11:15 a.m.–11:30 a.m. » Group Debrief & Closing Remarks Mona Bahouth, MD, Baltimore, MD

PL1: Neurology Year in Review Plenary Session

1.5

Location: Concorde B Learning Objectives: Three expert speakers will focus on the latest developments of interest to the clinician that have occurred in a specific subspecialty topic.

Lecture/Faculty: 10:00 a.m.–10:30 a.m. » Advances in Progressive MS Ilana B. Katz Sand, MD, New York, NY 10:30 a.m.–11:00 a.m. » Brain Health Costantino Iadecola, MD, New York, NY 11:00 a.m.–11:30 a.m. » Autoimmune Encephalitis: Diagnosis and Management Divyanshu Dubey, MD, FAAN, Rochester, MN

11:30 a.m.–1:00 p.m.

Exhibit Hall Lunch Location: Rivoli 11:45 a.m.–12:30 p.m.

Business Administrators Networking Session Location: Vendome B Learning Objectives: What is your practice’s biggest pain point? Come network with your peers to brainstorm solutions, identify best practices, and discuss other hot topics related to the business of neurology.

Lecture/Faculty: 11:45 a.m.–12:30 p.m. » Business Administrators Networking

11:45 a.m.–12:30 p.m.

APP Networking Session Location: Concorde A Learning Objectives: Join APPs and other professionals to discuss issues and solutions affecting advanced practice providers in neurology.

Lecture/Faculty: 11:45 a.m.–12:30 p.m. » APP Networking AAN.com/FCQuickLinks

9

FRIDAY, OCTOBER 27

Learning Objectives: Participants should learn about a common stumbling block to working in teams: conflict. Participants should learn about a neuroscience-based tool to work through, rather than avoid, conflict. The SCARF model involves five domains of human social experience: Status, Certainty, Autonomy, Relatedness and Fairness. Status is about relative importance to others. Certainty is about the ability to predict the future. Autonomy provides a sense of control.

Relatedness is a sense of safety with others.

Fairness is a perception of fair exchanges between people. Participants should be able to apply a neuroscience-based model to organizational conflict, reflect on procedures and practices that trigger a threat response in organizations, and develop action steps that help reduce social threat and maximize rewards for improved organizational leadership.

10:00 a.m.–11:30 a.m.

SCHEDULE

FRIDAY, OCTOBER 27 manifestations, learn to recognize acute unilateral vestibulopathy/ vestibular neuritis..

12:00 p.m.–12:20 p.m.

Exhibit Hall Industry Presentation Stage

Lecture/Faculty:

FRIDAY, OCTOBER 27

Location: Rivoli Learning Objectives: The stage will feature brief 20-minute presentations from industry companies on exciting pipeline updates. These programs are not accredited for continuing education by any organization. Additionally, Exhibit Hall Industry Presentation Stage program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2023 Fall Conference education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of preFDA drugs, or other research information that might be discussed.

Exhibit Hall Industry Presentation Stage are industry events.

Lecture/Faculty: 12:00 p.m.–12:20 p.m. » Industry Presentation Stage: Alexion, AstraZeneca Rare Disease

1.5

Location: Vendome A Learning Objectives: This update will review the latest recommendations for the diagnosis, management and treatment of common neuro-ophthalmologic problems such as the use of fundus cameras and optical coherence tomography in Neurology, idiopathic intracranial hypertension, optic neuritis and other causes of optic neuropathies and will provide tips for neuroophthalmic evaluations at bedside. Neuro-otology Update: During this update attedndees will review the framework for evaluating and diagnosing patients with dizziness and imbalance, learn to recognize and treat benign paroxysmal positional vertigo – a common condition with complex

10 #AANFC

1:00 p.m.–2:30 p.m.

C7: New Therapies for Migraine and Other Headache Disorders

1.5

Location: Concorde B Learning Objectives: Participants should become familiar with recent consensus and guidelines on new treatments in headache medicine, be able to discuss and review realworld use of new treatment options in headache medicine as well as real-world evidence of new treatment options in headache medicine, and be able to report about ongoing research in the field of headache medicine.

Lecture/Faculty:

1:00 p.m.–2:30 p.m.

C6: Neurology Update 3: Neuroophthalmology and Neuro-otology

1:00 p.m.–1:45 p.m. » Neuro-ophthalmology Valerie Biousse, MD, Atlanta, GA 1:45 p.m.–2:30 p.m. » Neuro-otology: Approach to the dizzy patient Joanna C. Jen, MD, PhD, New York, NY

1:00 p.m.–1:15 p.m. » Are We at a Consensus?

Jessica Ailani, MD, FAAN, McLean, VA 1:15 p.m.–1:55 p.m. » Real World Evidence of New Migraine Therapies Zubair Ahmed, MD, Cleveland, OH 1:55 p.m.–2:20 p.m. » Top Evidence in Headache Over the Past Year Rebecca C. Burch, MD, Burlington, VT 2:20 p.m.–2:30 p.m. » Ask the Questions, We Will Answer...

Jessica Ailani, MD, FAAN, McLean, VA Rebecca C. Burch, MD, Burlington, VT Zubair Ahmed, MD, Cleveland, OH

Information is accurate as of October 10, 2023, and is subject to change.

FRIDAY, OCTOBER 27 1:00 p.m.–2:30 p.m.

C8: Practice Management 3:

Reducing Administrative Burden

1.5

Location: Vendome B Learning Objectives: Updated description forthcoming. Please continue to check AAN.com for any updates.

Lecture/Faculty: 1:00 p.m.–2:30 p.m. » Reducing Administrative Burden Kavita Nair, PhD, FAAN, Aurora, CO Troy McCulloch, MBA, Bloomington, MN

2:30 p.m.–3:00 p.m.

Exhibit Hall Break

1:00 p.m.–2:30 p.m.

L3: Turning Conflict into

1.5

Location: Vendome C Learning Objectives: Participants should learn about a common stumbling block to working in teams: conflict. Participants should learn about a neuroscience-based tool to work through, rather than avoid, conflict. The SCARF model involves five domains of human social experience: Status, Certainty, Autonomy, Relatedness and Fairness. Status is about relative importance to others. Certainty is about the ability to predict the future. Autonomy provides a sense of control.

Relatedness is a sense of safety with others.

Fairness is a perception of fair exchanges between people. Participants should be able to apply a neuroscience-based model to organizational conflict, reflect on procedures and practices that trigger a threat response in organizations, and develop action steps that help reduce social threat and maximize rewards for improved organizational leadership.

Location: Rivoli 3:00 p.m.–4:30 p.m.

C9 : Neurology Update 4: Multiple Sclerosis and Autoimmune Neurology

1.5

Location: Vendome A Learning Objectives: Updated description forthcoming. Please continue to check AAN.com for any updates.

Lecture/Faculty: 3:00 p.m.–3:45 p.m. » Multiple Sclerosis Update Christina Azevedo, MD, FAAN, Los Angeles, CA 3:45 p.m.–4:30 p.m. » Autoimmune Neurology Stefanie Jordan Rodenbeck, MD, Indianapolis, IN

Lecture/Faculty: 1:00 p.m.–1:10 p.m. » Introduction & Icebreaker Jeffrey C. McClean, II, MD, FAAN, San Antonio, TX 1:10 p.m.–1:20 p.m. » Introduction to SCARF Ezgi Tiryaki, MD, FAAN, Minneapolis, MN

AAN.com/FCQuickLinks

11

FRIDAY, OCTOBER 27

Collaboration: A Neuroscience Based Tool to Better Lead Your Organization

1:20 p.m.–1:30 p.m. » Organization Level Case Study Jeffrey C. McClean, II, MD, FAAN, San Antonio, TX 1:30 p.m.–2:05 p.m. » Case Study Group Activity Ezgi Tiryaki, MD, FAAN, Minneapolis, MN 2:05 p.m.–2:25 p.m. » Discussion & Group Debrief Gabriele C. De Luca, MD, DPhil, FAAN, Oxford, United Kingdom 2:25 p.m.–2:30 p.m. » Summary & Closing Remarks Gabriele C. De Luca, MD, DPhil, FAAN, Oxford, United Kingdom

SCHEDULE

FRIDAY, OCTOBER 27

3:00 p.m.–4:30 p.m.

C10 : Artificial Intelligence in Clinical Neurology

3:00 p.m.–4:30 p.m.

1.5

Location: Concorde B Learning Objectives: Participants should understand and be familiar with common terminology for techniques used in artificial intelligence including deep learning, supervised learning, and unsupervised learning. An emphasis will be placed on statistical methods and metrics used to evaluate artificial intelligence models so that they can consider those metrics as part of their everyday practice. Current applications of artificial intelligence for diagnostic techniques, including imaging and EEG, will be examined.

FRIDAY, OCTOBER 27

Lecture/Faculty: 3:00 p.m.–3:05 p.m. » Introduction Sarah Mercaldo, PhD, Boston, MA 3:05 p.m.–3:45 p.m. » AI Fundamentals Sarah Mercaldo, PhD, Boston, MA 3:45 p.m.–4:15 p.m. » AI and Neurology Applications Sarah Mercaldo, PhD, Boston, MA 4:15 p.m.–4:30 p.m. » Questions and Answers Sarah Mercaldo, PhD, Boston, MA

Addressing Current Challenges in Healthcare

1.5

Location: Vendome C Learning Objectives: Participants will hear from top health care leaders on how they are addressing current challenges in health care, both locally and nationally, while maintaining their own wellbeing. Discussion topics will highlight leadership competencies needed for systems level leadership, including navigating systems, leading large scale change, setting strategy and influencing others. Participants should gain concrete strategies to ‘get a seat at the table’ while battling imposter syndrome, develop strategies to evaluate professional commitments in order to maintain personal wellbeing while affecting change, and discover different paths to affecting change in healthcare within a constrained environment.

Lecture/Faculty:

3:00 p.m.–4:30 p.m.

C11: Practice Management 4: Learning Health Care System

L4: Leadership Perspectives on

1.5

Location: Vendome B Learning Objectives: Participants should learn about the increasing presence of Learning Health Systems (LHS), and its role and implications on the future of care delivery, documentation, and reimbursement. An LHS is a health system in which internal data and experience are systematically integrated with external evidence, and that knowledge is put into practice. As a result, patients get higher quality, safer, and more efficient care.

3:00 p.m.–3:15 p.m. » Panelist Introductions Brad C. Klein, MD, MBA, FAAN, Abington, PA Lily Jung Henson, MD, MMM, FAAN, Augusta, GA Kavita Nair, PhD, FAAN, Aurora, CO 3:15 p.m.–3:45 p.m. » Panel Discussion Brad C. Klein, MD, MBA, FAAN, Abington, PA Lily Jung Henson, MD, MMM, FAAN, Augusta, GA Kavita Nair, PhD, FAAN, Aurora, CO 3:45 p.m.–4:30 p.m. » Audience Q&A Brad C. Klein, MD, MBA, FAAN, Abington, PA Lily Jung Henson, MD, MMM, FAAN, Augusta, GA Kavita Nair, PhD, FAAN, Aurora, CO

4:00 p.m.–5:30 p.m.

Exhibit Hall Reception Location: Rivoli Network with colleagues and find new connections while enjoying beverages and appetizers. Perfect way to start your evening!

Lecture/Faculty: 3:00 p.m.–4:30 p.m. » Learning Health Care System Jeffrey R. Buchhalter, MD, FAAN, Phoenix, AZ

12 #AANFC

Information is accurate as of October 10, 2023, and is subject to change.

FRIDAY, OCTOBER 27 5:45 p.m.–6:45 p.m.

Industry Therapeutic Update from Eisai: An Option for Intervention in Early Alzheimer’s Disease: MCI Due to AD or Mild AD Dementia Location: Concorde A

FRIDAY, OCTOBER 27

Learning Objectives: Review the Prescribing Information for LEQEMBI (lecanemab-irmb) for the treatment of MCI due to AD and mild AD dementia and highlight key considerations for clinical practice, including: Identifying appropriate patients for treatment with LEQEMBI Key efficacy and safety data from the Clarity AD study Important safety information, including boxed warning for ARIA Best practices for screening and management of ARIA Navigating the steps from diagnosis to treatment with LEQEMBI. Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2023 AAN Fall Conference education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

AAN.com/FCQuickLinks

13

It’s Time to Act

Once cognitive symptoms emerge Every 65 seconds, someone in the United States develops Alzheimer’s disease (AD), the fifth-leading cause of death in the United States among individuals aged 65 and older.1,2

EVALUATED TOO LATE AD diagnosis is delayed on average by 2-3 years after symptom onset and is often made only in the latter stages of the disease.3,4 With new therapies focusing earlier in the disease continuum, assessing cognitive impairment as early as possible is more important than ever.5

See what time hides at TimeHidesAlz.com

References: 1. Grabher BJ. Effects of Alzheimer’s disease on patients and their family. J Nucl Med Technol. 2018;46(4):335-340. 2. Alzheimer’s Association. 2022 Alzheimer’s disease facts and figures. Alzheimers Dement. 2022;18(4):700-789. 3. Sabbagh MN, Lue L-L, Fayard D, et al. Increasing precision of clinical diagnosis of Alzheimer’s disease using a combined algorithm incorporating clinical and novel biomarker data. Neurol Ther.

2017;6(suppl 1):S83-S95. 4. Boise L, Morgan DL, Kaye J, et al. Delays in the diagnosis of dementia: perspectives of family caregivers. Am J Alzheimers Dis Other Dement. 1999;14(1):20-26. 5. Aisen PS, Cummings J, Jack CR Jr, et al. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther. 2017;9(1):60. doi:10.1186/s13195-017-0283-5.

PP-AD-US-0553 08/2023 © Lilly USA, LLC 2023. All Rights Reserved.

SATURDAY, OCTOBER 28 7:00 a.m.–7:50 a.m.

Industry Therapeutic Update from Eli Lilly: It’s Not Me, It’s You. Communication Misalignment and Strategies to Close the Migraine Treatment Gap. Location: Concorde A

8:00 a.m.–9:30 a.m.

C12 : Neurology Update 5: Neurocritical Care and Concussion 1.5 Location: Vendome A Learning Objectives: Faculty will use a casebased approach to review some of the major advances in neurocritical care in late 2022 and 2023 including: the ICU management of large core thrombectomy stroke patients, the emerging evidence for minimally invasive clot evacuation in ICH, new evidence for BP control in hemorrhagic stroke, and an overview of the recently published AHA/ASA guidelines for aneurysm subarachnoid hemorrhage. Participants should be able to accurately conceptualize diagnostic approaches to concussion, augment their management options for patients with concussion, seek opportunities to evaluate and positively affect multiple outcomes

Lecture/Faculty: 8:00 a.m.–8:45 a.m. » Neurocritical Care Casey S.W. Albin, MD, Atlanta, GA 8:45 a.m.–9:30 a.m. » Concussion: A Practical Approach to Assessment, Management, Outcomes, and Expectations Vernon B. Williams, MD, FAAN, Los Angeles, CA

8:00 a.m.–9:30 a.m.

C13: Neurologic Conditions in Transgender Patients

1.5

Location: Concorde B Learning Objectives: Participations should be able to define terminology and concepts relevant to the care of transgender and gender diverse people, describe current best practices in the neurologic care of transgender and gender diverse people, and identify interventions to promote an inclusive clinical practice and workplace.

Lecture/Faculty: 8:00 a.m.–8:05 a.m. » Introduction Gwen W. Zeigler, DO, Albany, NY 8:05 a.m.–8:40 a.m. » General Neurological Considerations in Transgender and Gender Diverse Patients Gwen W. Zeigler, DO, Albany, NY 8:40 a.m.–9:15 a.m. » MS, Neuroimmunology, Neuroinfectious Disease, and Cultural Competency In Transgender and Gender Diverse Patients Em P. Harrington, MD, PhD, Columbus, OH 9:15 a.m.–9:30 a.m. » Questions and Answer Session Gwen W. Zeigler, DO, Albany, NY Em P. Harrington, MD, PhD, Columbus, OH

AAN.com/FCQuickLinks

15

SATURDAY, OCTOBER 28

Learning Objectives: Learn how you can make a difference in the lives of patients living with migraine. Join us for a presentation on why migraine is more than just headache days. We will examine factors that may contribute to the underdiagnosis and undertreatment of migraine and share clinical tools for discussing the impact of migraine with patients and creating a patientcentered treatment plan. This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2023 Fall Conference education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of preFDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

associated with concussive injury, and employ cognitive restructuring as an intervention in concussion management with knowledge of its impact on recovery.

SCHEDULE

SATURDAY, OCTOBER 28

8:00 a.m.–9:30 a.m.

C14: Practice Management 5: Artificial Intelligence

10:00 a.m.–11:30 a.m.

1.5

1.5

Location: Vendome B

Location: Concorde B

Learning Objectives: Updated description forthcoming. Please continue to check AAN.com for any updates.

Learning Objectives: This innovative case-based session will use short-format teaching session to highlight clinical and pharmacologic pearls in vascular neurology, including acute stroke therapy and secondary stroke prevention. This session will focus on both hemorrhagic and ischemic stroke, and review high-yield tips and learning points through the continuum of care—from prehospital to clinic follow up.

Lecture/Faculty: 8:00 a.m.–9:30 a.m. » Artificial Intelligence Jose M. Rocha, MHL, Medley, FL James F. Rini, MD, New Orleans, LA

9:30 a.m.–10:00 a.m.

Lecture/Faculty:

Exhibit Hall Break

10:00 a.m.–11:00 a.m. » Cerebrovascular Disease Casey S.W. Albin, MD, Atlanta, GA Shadi Yaghi, MD, Barrington, RI

Location: Rivoli

SATURDAY, OCTOBER 28

C16: Microlearning: Cerebrovascular Disease

10:00 a.m.–11:30 a.m.

C15: Neurology Update 6: Headache and Epilepsy

1.5

Location: Vendome A

10:00 a.m.–11:30 a.m.

C17: Practice Management 6: Building Service Lines

Learning Objectives: In the headache update, participants will review the recent perspectives on migraine management issues, facial pain, and COVID-related headache. The review will be followed by summarized updates in etiology and management of migraine, COVID-related headache, and facial pain. In the epilepsy update, participants will review the updated ILAE classification and definitions of epilepsy syndromes, then receive a summary of updates in etiology, treatment, and management of epilepsy.

Lecture/Faculty: 10:00 a.m.–10:45 a.m. » Headache Charles C. Flippen, II, MD, FAAN, Los Angeles, CA 10:45 a.m.–11:30 a.m. » Epilepsy Kelsey Marie Smith, MD, Rochester, MN

1.5

Location: Vendome B Learning Objectives: Explore the many aspects of developing services. Along with increasing opportunities for additional revenue streams, expanding service lines can improve patient care, increase access and deliver additional indirect benefits to your practice. Learners should gain an appreciation for a strategic process to analyze the potential to add a service line and carry out that plan from start to finish with several illustrative real world case studies.

Lecture/Faculty: 10:00 a.m.–11:30 a.m. » Building Service Lines Amy Rene Knighton, Savannah, GA Louis A. Tramontozzi, III, MD, Beverly, MA Leeann Garms, Raleigh, NC

11:30 a.m.–1:00 p.m.

Exhibit Hall Lunch Location: Rivoli

16 #AANFC

Information is accurate as of October 10, 2023, and is subject to change.

SATURDAY, OCTOBER 28 1:00 p.m.–2:30 p.m.

C18: Continuum® Test Your

Knowledge: A Multiple-choice Question Review 1

1:00 p.m.–2:30 p.m.

SA-

1.5

Location: Vendome A Learning Objectives: Participants should be able to increase and refresh their knowledge of the core topics of headache and stroke through presentation of common and not-so-common clinical problems, and learn to work through difficult clinical presentations both logically and successfully. This program complements Continuum Test Your Knowledge: A Multiplechoice Question Review 2 but covers independent topics.

Lecture/Faculty:

1:00 p.m.–2:30 p.m.

C19 : Practice Management 7: Coding

1.5

Location: Vendome B Learning Objectives: “Why do I need to know about coding?” It’s not why we went into medicine. However, it can make or break your professional practice. Let’s talk about how you can use coding to demonstrate the quality of our practice, enhance reimbursement, and improve your quality of life.

1.5

Location: Concorde B Learning Objectives: Participants should gain an understanding of the immunopathologic mechanisms leading to weakness in myasthenia gravis, be able to list newly FDA-approved myasthenia gravis treatments and define their mechanisms of action, and understand knowledge gaps in the therapeutic approach to myasthenia gravis and potential means of bridging them.

Lecture/Faculty: 1:00 p.m.–1:10 p.m. » Introduction A. Gordon Smith, MD, FAAN, Richmond, VA 1:10 p.m.–1:35 p.m. » Myasthenia Gravis: Immunopathology and Mechanisms of Disease Kevin O’Connor, New Haven, CT 1:35 p.m.–2:00 p.m. » The Myasthenia Gravis Therapeutic Pipeline: Current and Future Targeted Therapies Richard J. Nowak, MD, New Haven, CT 2:00 p.m.–2:20 p.m. » Translating Therapeutic Discoveries in Myasthenia Gravis into Daily Clinical Practice A. Gordon Smith, MD, FAAN, Richmond, VA 2:20 p.m.–2:30 p.m. » Questions and Answers A. Gordon Smith, MD, FAAN, Richmond, VA Richard J. Nowak, MD, New Haven, CT Kevin O’Connor, New Haven, CT

Lecture/Faculty: 1:00 p.m.–2:30 p.m. » Coding Jose M. Rocha, MHL, Medley, FL Katherine Coerver, MD, PhD, FAAN, Lone Tree, CO

AAN.com/FCQuickLinks

17

SATURDAY, OCTOBER 28

1:00 p.m.–1:45 p.m. » Headache Jennifer Bickel, MD, FAAN, Tampa, FL 1:45 p.m.–2:30 p.m. » Stroke Ania Busza, MD, PhD, Rochester, NY

N1: Neuroscience in the Clinic: Myasthenia Gravis: From Pathogenesis to Targeted Therapies

IS IT LEMS OR MG? Lambert-Eaton myasthenic syndrome (LEMS) and myasthenia gravis (MG) share several hallmark signs and symptoms, including muscle weakness and oculobulbar involvement.1,2

One way to differentiate these two immune-mediated neuromuscular disorders is to look for these specific signs and symptoms1,2 : LEMS

MG

Symmetrical muscle weakness

Caudal-to-cranial pattern of spread

Typically asymmetrical muscle weakness Cranial-to-caudal pattern of spread

Late-onset and mild oculobulbar involvement

Early and prominent oculobulbar involvement

Absent or diminished tendon reflexes

Preserved tendon reflexes

Autonomic dysfunction

No autonomic dysfunction

Transient improvement of muscle strength with exercise, with fatigue that follows Antibodies to voltage-gated calcium channels (VGCC) are usually found

Muscle weakness worsens with exercise

Antibodies to AChR or MuSK are usually found

SCAN THE CODE Discover another way to differentiate LEMS from MG with no-cost VGCC antibody testing from Catalyst Pharmaceuticals.

References: 1. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107. 2. Merino-Ramírez MÁ, Bolton CF. Review of the diagnostic challenges of Lambert-Eaton syndrome revealed through three case reports. Can J Neurol Sci. 2016;43(5):635-647.

© 2023 Catalyst Pharmaceuticals, Inc. All Rights Reserved.

Printed in USA. LEM-0127 August 2023

SUPPORTING PATIENTS WITH LEMS IN EVERY WAY WE CAN The right treatment and support go hand in hand

Catalyst Pharmaceuticals created Catalyst Pathways®, a free, personalized program designed to help you and your adult patients manage the unique challenges of Lambert-Eaton myasthenic syndrome (LEMS) through:

One-on-one support and education

Financial support programs

A dedicated team of specialists to navigate insurance

Patient Mentor Program

Find out more about all the ways Catalyst Pharmaceuticals is working to help support you and your patients.

To learn more, visit YourCatalystPathways.com.

Catalyst Pathways® is a registered trademark of Catalyst Pharmaceuticals, Inc. © 2023 Catalyst Pharmaceuticals, Inc. All Rights Reserved.

Printed in USA. CAT-0055 October 2023

SCHEDULE

SATURDAY, OCTOBER 28

1:00 p.m.–4:30 p.m.

C20 : Anti-amyloid Therapy Boot Camp

3.5

Location: Vendome C

3:00 p.m.–4:30 p.m.

SATURDAY, OCTOBER 28

Learning Objectives: Participants should be able to appraise major findings from recent clinical trials of anti-amyloid monoclonal antibody therapies in Alzheimer’s disease; understand imaging and fluid biomarkers relevant for treatment eligibility and monitoring; identify proposed clinical criteria for appropriate use of anti-amyloid therapies in clinical practice; summarize mechanisms, risk factors, and safety monitoring for amyloid-related imaging abnormalities; and assess practice-level adaptations needed for emerging AD therapies.

Lecture/Faculty: 1:00 p.m.–1:05 p.m. » Introduction Vijay K. Ramanan, MD, PhD, Rochester, MN 1:05 p.m.–1:50 p.m. » Background and Outcomes on the Phase 3 Trials for Lecanemab and Donanemab Jared R. Brosch, MD, Indianapolis, IN 1:50 p.m.–2:30 p.m. » Appropriate Use of Anti-Amyloid Monoclonal Antibodies in the Clinic Parichita Choudhury, MD, Sun City, AZ 2:30 p.m.–3:10 p.m. » Diagnosing and Managing ARIA with AntiAmyloid Therapies Petrice Mostardi Cogswell, MD, PhD, Rochester, MN 3:10 p.m.–3:40 p.m. » Practice, System, and Payer Adaptations with Emerging Treatments Vijay K. Ramanan, MD, PhD, Rochester, MN 3:40 p.m.–4:00 p.m. » Open Questions and Future Evolutions with Anti-Amyloid Therapies Vijay K. Ramanan, MD, PhD, Rochester, MN 4:00 p.m.–4:30 p.m. » Questions and Answers Vijay K. Ramanan, MD, PhD, Rochester, MN Parichita Choudhury, MD, Sun City, AZ Petrice Mostardi Cogswell, MD, PhD, Rochester, MN Jared R. Brosch, MD, Indianapolis, IN

This program is supported in part by educational grants from Eisai Inc. and Lilly.

The Academy was solely responsible, with no influence from the industry supporters, for the selection of content, format, presenters, and moderators of this CME

20 #AANFC

program, and the speakers have not been contacted or influenced in any way by the SAindustry supporters with regard to this CME program.

C21: Continuum® Test Your

Knowledge: A Multiple-choice Question Review 2

1.5

Location: Vendome A Learning Objectives: Participants should be able to increase and refresh their knowledge of the core topics of multiple sclerosis and movement disorders through presentation of common and not-so-common clinical problems, and learn to work through difficult clinical presentations both logically and successfully. This program complements Continuum Test Your Knowledge: A Multiple-choice Question Review 1 but covers independent topics.

Lecture/Faculty: 3:00 p.m.–3:45 p.m. » Multiple Sclerosis Augusto A. Miravalle, MD, FAAN, Chicago, IL 3:45 p.m.–4:30 p.m. » Movement Disorders Jeffrey B. Ratliff, MD, FAAN, Philadelphia, PA

3:00 p.m.–4:30 p.m.

C22 : Infections of the Nervous System

1.5

Location: Concorde B Learning Objectives: Participants should be able to understand key concepts in the evaluation and workup of neuroinfectious diseases; define radiographic patterns in a variety of common neuroinfectious diseases; define key differential diagnoses in common neuroinfectious diseases; and describe key clinical features of common neuroinfectious diseases seen in the acute and chronic setting.

Lecture/Faculty: 3:00 p.m.–4:30 p.m. » Infections of the Nervous System Greer Waldrop, MD, San Francisco, CA

Information is accurate as of October 10, 2023, and is subject to change.

SATURDAY, OCTOBER 28 3:00 p.m.–4:30 p.m.

C23: Practice Management 8: Beyond the Bedside: Integrating APPs

1.5

Location: Vendome B Learning Objectives: Neurology physicianowned private practices continue to decrease in number, which makes it harder for practices to stay in business. To keep a practice thriving, it must stand out amongst the many other systemowned practices. Presenters will moderate active discussions on unique ways to enhance your practice.

Lecture/Faculty: 3:00 p.m.–4:30 p.m. » Beyond the Bedside: Integrating APPs Louis A. Tramontozzi, III, MD, Beverly, MA Shannon Anderson, PA, Portland, OR

AAN.com/FCQuickLinks

21

SCHEDULE

SUNDAY, OCTOBER 29

7:30 a.m.–9:00 a.m.

C24: Neurology Update 7: Movement Disorders and Infectious Disease

1.5

Location: Concorde A

SUNDAY, OCTOBER 29

Learning Objectives: Participants should gain an overview of the major developments in movement disorders over the last 12 months, along with an update on the pharmacologic treatment of Parkinson’s disease. Participants should also be able to understand advances in treatments for neurologic infections, including progressive multifocal leukoencephalopathy, HTLV-1-associated myelopathy, and cryptococcal meningitis. as well as new research on what makes some people more susceptible to viral encephalitis.

Lecture/Faculty: 7:30 a.m.–8:15 a.m. » Movement Disorders Andres Felipe Deik Acosta Madiedo, MD, FAAN, Philadelphia, PA 8:15 a.m.–9:00 a.m. » Infectious Disease Michael R. Wilson, MD, FAAN, San Francisco, CA

7:30 a.m.–9:00 a.m.

C25: Epilepsy Therapy Update Location: Concorde B

1.5

Learning Objectives: Participants should become familiar with all currently approved antiseizure medications in the US and how to tailor each drug to the correct patient with seizures; be aware of all surgical modalities, including minimally invasive therapies; and become familiar with neuromodulatory devices for the treatment of epilepsy, including responsive neurostimulation and deep brain stimulation.

8:15 a.m.–8:55 a.m. » Update in Neuromodulation and Surgery Meriem K. Bensalem Owen, MD, Lexington, KY 8:55 a.m.–9:00 a.m. » Discussion Anteneh Mekonnen Feyissa, MD, MSc, FAAN, Jacksonville, FL Meriem K. Bensalem Owen, MD, Lexington, KY

9:30 a.m.–11:00 a.m.

C26: Neurology Update 8:

Neuromuscular Disease and Autonomic Disorders

1.5

Location: Concorde A Learning Objectives: Participants should become familiar with expanding options in the treatment of myasthenia gravis; enhance their understanding of management considerations for patients with motor neuron disease; and acquire clinical pearls in the diagnosis and treatment of myopathies, neuropathies, and disorders of the neuromuscular junction. Participants should also learn how to develop a diagnostic approach to the patient with autonomic failure; understand the natural history and disease trajectory of patients with autonomic failure; and be able to develop a differential diagnosis of patients presenting with autonomic features.

Lecture/Faculty: 9:30 a.m.–10:15 a.m. » Neuromuscular Robert M. Pascuzzi, MD, FAAN, Indianapolis, IN 10:15 a.m.–11:00 a.m. » Autonomic Disorders Roy L. Freeman, MD, Boston, MA

Lecture/Faculty: 7:30 a.m.–7:35 a.m. » Introduction Anteneh Mekonnen Feyissa, MD, MSc, FAAN, Jacksonville, FL 7:35 a.m.–8:15 a.m. » Update in ASMs and Immunotherapy Anteneh Mekonnen Feyissa, MD, MSc, FAAN, Jacksonville, FL

22 #AANFC

Information is accurate as of October 10, 2023, and is subject to change.

SUNDAY, OCTOBER 29 9:30 a.m.–11:00 a.m.

C27: Myelin Oligodendrocyte

Glycoprotein Antibody Disorders (MOGAD)

1.5

Location: Concorde B Learning Objectives: Participants should gain an understanding of the new international MOGAD diagnostic criteria and their application in clinical practice using both didactic and case examples; be able to illustrate key neuroimaging features of MOGAD; and discuss current therapies and future clinical trials for pediatric and adult MOGAD. Lecture/Faculty:

SUNDAY, OCTOBER 29

9:30 a.m.–9:35 a.m. » Welcome and Introduction Brenda Banwell, MD, FAAN, Philadelphia, PA 9:35 a.m.–10:00 a.m. » MOGAD Diagnostic Criteria Giulia Fadda, MD, Ottawa, ON, Canada 10:00 a.m.–10:25 a.m. » Imaging Features of MOGAD and Differential Eoin P. Flanagan, MBBCh, FAAN, Rochester, MN 10:25 a.m.–10:45 a.m. » Clinical Features and Management of MOGAD Brenda Banwell, MD, FAAN, Philadelphia, PA 10:50 a.m.–11:00 a.m. » Question and Answers Brenda Banwell, MD, FAAN, Philadelphia, PA

AAN.com/FCQuickLinks

23

PLEASE JOIN US lecanemab-irmb) INJECTION FOR INTRAVENOUS USE

LEQEMBI® as an Option for Intervention in Early Alzheimer’s Disease: MCI Due to AD or Mild AD Dementia Program Information

Presented by

Friday, October 27, 2023

Justin Moon, MD

5:45–6:45 PM PT Paris Las Vegas Hotel Concorde A Las Vegas, NV 89109

Scan to Register Now

Director Department of Neurology Denver Neurological Clinic Denver, CO

Program Objectives Review the Prescribing Information for LEQEMBI® (lecanemab-irmb) for the treatment of MCI due to AD and mild AD dementia and highlight key considerations for clinical practice, including: • • • • •

Identifying appropriate patients for treatment with LEQEMBI Key efficacy and safety data from the Clarity AD study Important Safety Information, including Boxed WARNING for ARIA Best practices for screening and management of ARIA Navigating the steps from diagnosis to treatment with LEQEMBI

Please visit us at Booth #318 for more information about Eisai and LEQEMBI INDICATION LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

SELECT SAFETY INFORMATION WARNING: AMYLOID RELATED IMAGING ABNORMALITIES (ARIA) • Monoclonal antibodies directed against aggregated forms of amyloid beta, including LEQEMBI, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur. Serious intracerebral hemorrhages >1 cm, some of which have been fatal, have been observed in patients treated with this class of medications. h Apolipoprotein E ɛ4 (ApoE ɛ4) Homozygotes: Patients who are ApoE ɛ4 homozygotes (approximately 15% of Alzheimer’s disease patients) treated with this class of medications, including LEQEMBI, have a higher incidence of ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and noncarriers.

Testing for ApoE ɛ4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed, they can still be treated with LEQEMBI; however, it cannot be determined if they are ApoEεɛ4 homozygotes and at higher risk for ARIA. • Consider the benefit of LEQEMBI for the treatment of Alzheimer’s disease and potential risk of serious adverse events associated with ARIA when deciding to initiate treatment with LEQEMBI.

CONTRAINDICATION LEQEMBI is contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients of LEQEMBI. Reactions have included angioedema and anaphylaxis.

Please see Select Safety Information and Brief Summary of Prescribing Information for LEQEMBI, including Boxed WARNING, on adjacent pages.

SELECT SAFETY INFORMATION (CONT’D) WARNINGS AND PRECAUTIONS AMYLOID RELATED IMAGING ABNORMALITIES • LEQEMBI can cause ARIA-E and ARIA-H. ARIA-E can be observed on MRI as brain edema or sulcal effusions, and ARIA-H as microhemorrhage and superficial siderosis. ARIA can occur spontaneously in patients with Alzheimer’s disease. ARIA-H associated with monoclonal antibodies directed against aggregated forms of beta amyloid generally occurs in association with an occurrence of ARIA-E. ARIA-H and ARIA-E can occur together.

• ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events, including seizure and status epilepticus, rarely can occur. Reported symptoms associated with ARIA may include headache, confusion, visual changes, dizziness, nausea, and gait difficulty. Focal neurologic deficits may also occur. Symptoms associated with ARIA usually resolve over time.

ARIA Monitoring and Dose Management Guidelines • Obtain recent baseline brain magnetic resonance imaging (MRI) prior to initiating treatment with LEQEMBI. Obtain an MRI prior to the 5th, 7th and 14th infusions.

• Recommendations for dosing in patients with ARIA-E and ARIA-H depend on clinical symptoms and radiographic severity. Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI. • Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment with LEQEMBI. If a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including MRI if indicated. If ARIA is observed on MRI, careful clinical evaluation should be performed prior to continuing treatment.

• There is no experience in patients who continued dosing through symptomatic ARIA-E or through asymptomatic, but radiographically severe, ARIA-E. There is limited experience in patients who continued dosing through asymptomatic but radiographically mild to moderate ARIA-E. There are limited data in dosing patients who experienced recurrent ARIA-E. Incidence of ARIA • In Study 2, symptomatic ARIA occurred in 3% (29/898) of LEQEMBItreated patients. Serious symptoms associated with ARIA were reported in 0.7% (6/898) of patients treated with LEQEMBI. Clinical symptoms associated with ARIA resolved in 79% (23/29) of patients during the period of observation.

• Including asymptomatic radiographic events, ARIA was observed in LEQEMBI: 21% (191/898); placebo: 9% (84/897). ARIA-E was observed in LEQEMBI: 13% (113/898); placebo: 2% (15/897). ARIA-H was observed in LEQEMBI: 17% (152/898); placebo: 9% (80/897).

There was no increase in isolated ARIA-H for LEQEMBI vs placebo.

ApoE ɛ4 Carrier Status and Risk of ARIA • In Study 2, 16% (141/898) of patients in the LEQEMBI arm were ApoE ɛ4 homozygotes, 53% (479/898) were heterozygotes, and 31% (278/898) were noncarriers.

• The incidence of ARIA was higher in ApoE ɛ4 homozygotes (LEQEMBI: 45%; placebo: 22%) than in heterozygotes (LEQEMBI: 19%; placebo: 9%) and noncarriers (LEQEMBI: 13%; placebo: 4%). Among patients treated with LEQEMBI, symptomatic ARIA-E occurred in 9% of ApoE ɛ4 homozygotes compared with 2% of heterozygotes and 1% of noncarriers. Serious events of ARIA occurred in 3% of ApoE ɛ4 homozygotes, and approximately 1% of heterozygotes and noncarriers.

• The recommendations on management of ARIA do not differ between ApoE ɛ4 carriers and noncarriers.

Radiographic Findings • The majority of ARIA-E radiographic events occurred early in treatment (within the first 7 doses), although ARIA can occur at any time and patients can have more than 1 episode. The maximum radiographic severity of ARIA-E in patients treated with LEQEMBI was mild in 4% (37/898), moderate in 7% (66/898), and severe in 1% (9/898). Resolution on MRI occurred in 52% of ARIA-E patients by 12 weeks, 81% by 17 weeks, and 100% overall after detection. The maximum radiographic severity of ARIA-H microhemorrhage in LEQEMBI-treated patients was mild in 9% (79/898), moderate in 2% (19/898), and severe in 3% (28/898) of patients; superficial siderosis was mild in 4% (38/898), moderate in 1% (8/898), and severe in 0.4% (4/898). Among LEQEMBI-treated patients, the rate of severe radiographic ARIA-E was highest in ApoE ɛ4 homozygotes 5% (7/141), compared to heterozygotes 0.4% (2/479) or noncarriers 0% (0/278). Among LEQEMBI-treated patients, the rate of severe radiographic ARIA-H was highest in ApoE ɛ4 homozygotes 13.5% (19/141), compared to heterozygotes 2.1% (10/479) or noncarriers 1.1% (3/278).

Intracerebral Hemorrhage • Intracerebral hemorrhage >1 cm in diameter was reported in 0.7% (6/898) of patients in Study 2 after treatment with LEQEMBI

compared to 0.1% (1/897) on placebo. Fatal events of intracerebral hemorrhage in patients taking LEQEMBI have been reported.

Concomitant Antithrombotic Medication: • In Study 2, baseline use of antithrombotic medication (aspirin, other antiplatelets, or anticoagulants) was allowed if the patient was on a stable dose. The majority of exposures to antithrombotic medications were to aspirin. Antithrombotic medications did not increase the risk of ARIA with LEQEMBI. The incidence of intracerebral hemorrhage was 0.9% (3/328 patients) in patients taking LEQEMBI with a concomitant antithrombotic medication at the time of the event compared to 0.6% (3/545 patients) in those who did not receive an antithrombotic. Patients taking LEQEMBI with an anticoagulant alone or combined with an antiplatelet medication or aspirin had an incidence of intracerebral hemorrhage of 2.5% (2/79 patients) compared to none in patients who received placebo.

• Because intracerebral hemorrhages >1 cm in diameter have been observed in patients taking LEQEMBI, additional caution should be exercised when considering the administration of anticoagulants or a thrombolytic agent (e.g., tissue plasminogen activator) to a patient already being treated with LEQEMBI. Other Risk Factors for Intracerebral Hemorrhage: • Patients were excluded from enrollment in Study 2 for findings on neuroimaging that indicated an increased risk for intracerebral hemorrhage. These included findings suggestive of cerebral amyloid angiopathy (prior cerebral hemorrhage >1 cm in greatest diameter, >4 microhemorrhages, superficial siderosis, vasogenic edema) or other lesions (aneurysm, vascular malformation) that could potentially increase the risk of intracerebral hemorrhage.

The presence of an ApoE ɛ4 allele is also associated with cerebral amyloid angiopathy, which has an increased risk for intracerebral hemorrhage. Caution should be exercised when considering the use of LEQEMBI in patients with factors that indicate an increased risk for intracerebral hemorrhage and in particular for patients who need to be on anticoagulant therapy.

HYPERSENSITIVITY REACTIONS Hypersensitivity reactions, including angioedema, bronchospasm, and anaphylaxis, have occurred in LEQEMBI-treated patients.

Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction, and initiate appropriate therapy.

INFUSION-RELATED REACTIONS • In Study 2, infusion-related reactions were observed in LEQEMBI: 26% (237/898); placebo: 7% (66/897), and the majority of cases in LEQEMBI-treated patients (75%, 178/237) occurred with the first infusion. Infusion-related reactions were mostly mild (69%) or moderate (28%) in severity. Infusion-related reactions resulted in discontinuations in 1% (12/898) of LEQEMBI-treated patients.

Symptoms of infusion-related reactions included fever and flulike symptoms (chills, generalized aches, feeling shaky, and joint pain), nausea, vomiting, hypotension, hypertension, and oxygen desaturation.

• In the event of an infusion-related reaction, the infusion rate may be reduced, or the infusion may be discontinued, and appropriate therapy initiated as clinically indicated. Prophylactic treatment with antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, or corticosteroids prior to future infusions may be considered.

ADVERSE REACTIONS • In Study 2, the most common adverse reaction leading to discontinuation of LEQEMBI was ARIA-H microhemorrhages that led to discontinuation in 2% (15/898) of patients treated with LEQEMBI compared to <1% (1/897) of patients on placebo.

• In Study 2, the most common adverse reactions reported in ≥5% of patients treated with LEQEMBI (N=898) and ≥2% higher than placebo (N=897) were infusion-related reactions (LEQEMBI: 26%; placebo: 7%), ARIA-H (LEQEMBI: 14%; placebo: 8%), ARIA-E (LEQEMBI: 13%; placebo: 2%), headache (LEQEMBI: 11%; placebo: 8%), superficial siderosis of central nervous system (LEQEMBI: 6%; placebo: 3%), rash (LEQEMBI: 6%; placebo: 4%), and nausea/ vomiting (LEQEMBI: 6%; placebo: 4%).

Please see Brief Summary of Prescribing Information for LEQEMBI, including Boxed WARNING, on adjacent pages.

SPEAKER PROGRAM GUIDELINES

A meal may be offered. Alcohol will not be provided.

Eisai complies with all relevant laws, regulations, and codes of conduct. In some jurisdictions, meals may be prohibited. (e.g., VT, U.S. Depts. of Veterans Affairs & Defense), capped (MN, NJ) or reportable (CT, DC, MA, NV). If you are a licensed healthcare professional in MN, NJ or VT, employed by U.S. Dept. of Veterans Affairs or Defense or other jurisdiction that may prohibit or cap meals, please identify yourself to an Eisai representative.

LEQEMBI® (lecanemab-irmb) injection, for intravenous use. Rx Only.

The following is a Brief Summary; refer to full Prescribing Information for complete product information.

WARNING: AMYLOID RELATED IMAGING ABNORMALITIES Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur. Serious intracerebral hemorrhages, some of which have been fatal, have been observed in patients treated with this class of medications [see Warnings and Precautions (5.1), Adverse Reactions (6.1)].

ApoE ε4 Homozygotes Patients who are apolipoprotein E ε4 (ApoE ε4) homozygotes (approximately 15% of Alzheimer’s disease patients) treated with this class of medications, including LEQEMBI, have a higher incidence of ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and noncarriers. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed they can still be treated with LEQEMBI; however, it cannot be determined if they are ApoE ε4 homozygotes and at higher risk for ARIA [see Warnings and Precautions (5.1)].

Consider the benefit of LEQEMBI for the treatment of Alzheimer’s disease and potential risk of serious adverse events associated with ARIA when deciding to initiate treatment with LEQEMBI [see Warnings and Precautions (5.1)].

1 INDICATIONS AND USAGE LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

2 DOSAGE AND ADMINISTRATION 2.1 Patient Selection Confirm the presence of amyloid beta pathology prior to initiating treatment 2.2 Dosing Instructions The recommended dosage of LEQEMBI is 10 mg/kg that must be diluted then administered as an intravenous infusion over approximately one hour, once every two weeks.

If an infusion is missed, administer the next dose as soon as possible.

2.3 Monitoring and Dosing Interruption for Amyloid Related Imaging Abnormalities LEQEMBI can cause amyloid related imaging abnormalities-edema (ARIA-E) and -hemosiderin deposition (ARIA-H) [see Warnings and Precautions (5.1)].

Monitoring for ARIA Obtain a recent baseline brain magnetic resonance imaging (MRI) prior to initiating treatment with LEQEMBI. Obtain an MRI prior to the 5th, 7th, and 14th infusions. If a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including an MRI if indicated.

Recommendations for Dosing Interruptions in Patients with ARIA ARIA-E The recommendations for dosing interruptions for patients with ARIA-E are provided in Table 1.

monoclonal antibodies directed against aggregated forms of beta amyloid generally occurs in association with an occurrence of ARIA-E. ARIA-H of any cause and ARIA-E can occur together.

ARIA usually occurs early in treatment and is usually asymptomatic, although serious and lifethreatening events, including seizure and status epilepticus, rarely can occur. When present, reported symptoms associated with ARIA may include headache, confusion, visual changes, dizziness, nausea, and gait difficulty. Focal neurologic deficits may also occur. Symptoms associated with ARIA usually resolve over time. The risk of ARIA, including symptomatic and serious ARIA, is increased in apolipoprotein E ε4 (ApoE ε4) homozygotes. In addition to ARIA, intracerebral hemorrhages greater than 1 cm in diameter have occurred in patients treated with LEQEMBI. Consider the benefit of LEQEMBI for the treatment of Alzheimer’s disease and potential risk of serious adverse events associated with ARIA when deciding to initiate treatment with LEQEMBI. Incidence of ARIA Symptomatic ARIA occurred in 3% (29/898) of patients treated with LEQEMBI in Study 2.

Serious symptoms associated with ARIA were reported in 0.7% (6/898) of patients treated with LEQEMBI. Clinical symptoms associated with ARIA resolved in 79% (23/29) of patients during the period of observation. Similar findings were observed in Study 1.

Including asymptomatic radiographic events, ARIA was observed in 21% (191/898) of patients treated with LEQEMBI, compared to 9% (84/897) of patients on placebo in Study 2.

ARIA-E was observed in 13% (113/898) of patients treated with LEQEMBI compared with 2% (15/897) of patients on placebo. ARIA-H was observed in 17% (152/898) of patients treated with LEQEMBI compared with 9% (80/897) of patients on placebo. There was no increase in isolated ARIA-H (i.e., ARIA-H in patients who did not also experience ARIA-E) for LEQEMBI compared to placebo.

Clinical Symptom Severity Categories: Mild: discomfort noticed, but no disruption of normal daily activity.

Moderate: discomfort sufficient to reduce or affect normal daily activity.

Severe: incapacitating, with inability to work or to perform normal daily activity.

2 See Table 3 for MRI severity [Warnings and Precautions (5.1)].

3 Suspend until MRI demonstrates radiographic resolution and symptoms, if present, resolve; consider a follow-up MRI to assess for resolution 2 to 4 months after initial identification. Resumption of dosing should be guided by clinical judgment

ApoE ε4 Carrier Status and Risk of ARIA Approximately 15% of Alzheimer’s disease patients are ApoE ε4 homozygotes. In Study 2, 16% (141/898) of patients in the LEQEMBI arm were ApoE ε4 homozygotes, 53% (479/898) were heterozygotes, and 31% (278/898) were noncarriers. The incidence of ARIA was higher in ApoE ε4 homozygotes (45% on LEQEMBI vs. 22% on placebo) than in heterozygotes (19% on LEQEMBI vs 9% on placebo) and noncarriers (13% on LEQEMBI vs 4% on placebo). Among patients treated with LEQEMBI, symptomatic ARIA-E occurred in 9% of ApoE ε4 homozygotes compared with 2% of heterozygotes and 1% noncarriers. Serious events of ARIA occurred in 3% of ApoE ε4 homozygotes, and approximately 1% of heterozygotes and noncarriers.

The recommendations on management of ARIA do not differ between ApoE ε4 carriers and noncarriers [see Dosage and Administration (2.3)]. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed they can still be treated with LEQEMBI; however, it cannot be determined if they are ApoE ε4 homozygotes and at higher risk for ARIA. An FDA-authorized test for the detection of ApoE ε4 alleles to identify patients at risk of ARIA if treated with LEQEMBI is not currently available. Currently available tests used to identify ApoE ε4 alleles may vary in accuracy and design.

ARIA-H The recommendations for dosing interruptions for patients with ARIA-H are provided in Table 2.

Radiographic Findings The radiographic severity of ARIA associated with LEQEMBI was classified by the criteria shown in Table 3.

Table 1: Dosing Recommendations for Patients with ARIA-E Clinical Symptom Severity1

ARIA-E Severity on MRI2 Mild

Moderate

Asymptomatic

May continue dosing

Suspend dosing3

Mild

May continue dosing based on clinical judgment

Suspend dosing

Moderate or Severe

Suspend dosing3

Severe Suspend dosing3

3

1

Table 2: Dosing Recommendations for Patients with ARIA-H

Table 3: ARIA MRI Classification Criteria

Clinical Symptom Severity

ARIA-H Severity on MRI1 Mild

Moderate

Severe

Asymptomatic

May continue dosing

Suspend dosing2

Suspend dosing3

Symptomatic

Suspend dosing2

Suspend dosing2

ARIA Type

Radiographic Severity Mild

Moderate

Severe

ARIA-E

FLAIR hyperintensity confined to sulcus and/or cortex/ subcortex white matter in one location <5 cm

FLAIR hyperintensity 5 to 10 cm in single greatest dimension, or more than 1 site of involvement, each measuring <10 cm

FLAIR hyperintensity >10 cm with associated gyral swelling and sulcal effacement. One or more separate/ independent sites of involvement may be noted

ARIA-H microhemorrhage

≤ 4 new incident microhemorrhages

5 to 9 new incident microhemorrhages

10 or more new incident microhemorrhages

ARIA-H 1 focal area of superficial siderosis superficial siderosis

2 focal areas of superficial siderosis

>2 areas of superficial siderosis

See Table 3 for MRI severity [Warnings and Precautions (5.1)].

Suspend until MRI demonstrates radiographic stabilization and symptoms, if present, resolve; resumption of dosing should be guided by clinical judgment; consider a follow-up MRI to assess for stabilization 2 to 4 months after initial identification.

3 Suspend until MRI demonstrates radiographic stabilization and symptoms, if present, resolve; use clinical judgment in considering whether to continue treatment or permanently discontinue LEQEMBI.

1

2

In patients who develop intracerebral hemorrhage greater than 1 cm in diameter during treatment with LEQEMBI, suspend dosing until MRI demonstrates radiographic stabilization and symptoms, if present, resolve. Use clinical judgment in considering whether to continue treatment after radiographic stabilization and resolution of symptoms or permanently discontinue LEQEMBI. 3 DOSAGE FORMS AND STRENGTHS LEQEMBI is a clear to opalescent and colorless to pale yellow solution, available as: • Injection: 500 mg/5 mL (100 mg/mL) in a single-dose vial • Injection: 200 mg/2 mL (100 mg/mL) in a single-dose vial 4 CONTRAINDICATIONS LEQEMBI is contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients of LEQEMBI. Reactions have included angioedema and anaphylaxis [see Warnings and Precautions (5.2)].

5 WARNINGS AND PRECAUTIONS 5.1 Amyloid Related Imaging Abnormalities Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E), which can be observed on MRI as brain edema or sulcal effusions, and ARIA with hemosiderin deposition (ARIA-H), which includes microhemorrhage and superficial siderosis.

ARIA can occur spontaneously in patients with Alzheimer’s disease. ARIA-H associated with

The majority of ARIA-E radiographic events occurred early in treatment (within the first 7 doses), although ARIA can occur at any time and patients can have more than 1 episode. The maximum radiographic severity of ARIA-E in patients treated with LEQEMBI was mild in 4% (37/898) of patients, moderate in 7% (66/898) of patients, and severe in 1% (9/898) of patients. Resolution on MRI occurred in 52% of ARIA-E patients by 12 weeks, 81% by 17 weeks, and 100% overall after detection. The maximum radiographic severity of ARIA-H microhemorrhage in patients treated with LEQEMBI was mild in 9% (79/898), moderate in 2% (19/898), and severe in 3% (28/898) of patients; superficial siderosis was mild in 4% (38/898), moderate in 1% (8/898), and severe in 0.4% (4/898). Among patients treated with LEQEMBI, the rate of severe radiographic ARIA-E was highest in ApoE ε4 homozygotes 5% (7/141), compared to heterozygotes 0.4% (2/479) or noncarriers 0% (0/278). Among patients treated with LEQEMBI, the rate of severe radiographic ARIA-H was highest in ApoE ε4 homozygotes 13.5% (19/141), compared to heterozygotes 2.1% (10/479) or noncarriers 1.1% (3/278).

Intracerebral Hemorrhage Intracerebral hemorrhage greater than 1 cm in diameter was reported in 0.7% (6/898) of patients

in Study 2 after treatment with LEQEMBI compared to 0.1% (1/897) on placebo. Fatal events of intracerebral hemorrhage in patients taking LEQEMBI have been observed.

LEQEMBI compared to <1% (1/897) of patients on placebo. Adverse reactions reported in Study 2 are shown in Table 4.

Concomitant Antithrombotic Medication In Study 2, baseline use of antithrombotic medication (aspirin, other antiplatelets, or anticoagulants) was allowed if the patient was on a stable dose. The majority of exposures to antithrombotic medications were to aspirin. Antithrombotic medications did not increase the risk of ARIA with LEQEMBI. The incidence of intracerebral hemorrhage was 0.9% (3/328 patients) in patients taking LEQEMBI with a concomitant antithrombotic medication at the time of the event compared to 0.6% (3/545 patients) in those who did not receive an antithrombotic. Patients taking LEQEMBI with an anticoagulant alone or combined with an antiplatelet medication or aspirin had an incidence of intracerebral hemorrhage of 2.5% (2/79 patients) compared to none in patients who received placebo.

Because intracerebral hemorrhages greater than 1 cm in diameter have been observed in patients taking LEQEMBI, additional caution should be exercised when considering the administration of anticoagulants or a thrombolytic agent (e.g., tissue plasminogen activator) to a patient already being treated with LEQEMBI.

Table 4: Adverse Reactions Reported in at Least 5% of Patients Treated With LEQEMBI 10 mg/kg Every Two Weeks and at Least 2% Higher than Placebo in Study 2

Other Risk Factors for Intracerebral Hemorrhage Patients were excluded from enrollment in Study 2 for findings on neuroimaging that indicated an increased risk for intracerebral hemorrhage. These included findings suggestive of cerebral amyloid angiopathy (prior cerebral hemorrhage greater than 1 cm in greatest diameter, more than 4 microhemorrhages, superficial siderosis, vasogenic edema) or other lesions (aneurysm, vascular malformation) that could potentially increase the risk of intracerebral hemorrhage.

The presence of an ApoE ε4 allele is also associated with cerebral amyloid angiopathy, which has an increased risk for intracerebral hemorrhage.

Caution should be exercised when considering the use of LEQEMBI in patients with factors that indicate an increased risk for intracerebral hemorrhage and in particular for patients who need to be on anticoagulant therapy.

Monitoring and Dose Management Guidelines Recommendations for dosing in patients with ARIA-E depend on clinical symptoms and radiographic severity [see Dosage and Administration (2.3)]. Recommendations for dosing in patients with ARIA-H depend on the type of ARIA-H and radiographic severity [see Dosage and Administration (2.3)]. Use clinical judgment in considering whether to continue dosing in patients with recurrent ARIA-E. Baseline brain MRI and periodic monitoring with MRI are recommended [see Dosage and Administration (2.3)]. Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment with LEQEMBI. If a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including MRI if indicated. If ARIA is observed on MRI, careful clinical evaluation should be performed prior to continuing treatment.

There is no experience in patients who continued dosing through symptomatic ARIA-E, or through asymptomatic but radiographically severe ARIA-E. There is limited experience in patients who continued dosing through asymptomatic but radiographically mild to moderate ARIA-E. There are limited data in dosing patients who experienced recurrent ARIA-E. The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) is a voluntary providerenrolled patient registry that collects information on treatments for Alzheimer’s disease, including LEQEMBI. Providers may obtain information about the registry at www.alz-net.org or contact alz-net@acr.org.

5.2 Hypersensitivity Reactions Hypersensitivity reactions, including angioedema, bronchospasm, and anaphylaxis, have occurred in patients who were treated with LEQEMBI. Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction, and initiate appropriate therapy. LEQEMBI is contraindicated in patients with a history of serious hypersensitivity to lecanemab-irmb or to any of the excipients of LEQEMBI. 5.3 Infusion-Related Reactions In Study 2, infusion-related reactions were observed in 26% (237/898) of patients treated with LEQEMBI compared to 7% (66/897) of patients on placebo; and the majority (75%, 178/237) occurred with the first infusion. Infusion-related reactions were mostly mild (69%) or moderate (28%) in severity. Infusion-related reactions resulted in discontinuations in 1% (12/898) of patients treated with LEQEMBI. Symptoms of infusion-related reactions include fever and flu-like symptoms (chills, generalized aches, feeling shaky, and joint pain), nausea, vomiting, hypotension, hypertension, and oxygen desaturation.

After the first infusion in Study 1, 38% of patients treated with LEQEMBI had transient decreased lymphocyte counts to less than 0.9 x109/L compared to 2% in patients on placebo, and 22% of patients treated with LEQEMBI had transient increased neutrophil counts to greater than 7.9 x109/L compared to 1% of patients on placebo. Lymphocyte and neutrophil counts were not obtained after the first infusion in Study 2.

In the event of an infusion-related reaction, the infusion rate may be reduced, or the infusion may be discontinued, and appropriate therapy initiated as clinically indicated. Prophylactic treatment with antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, or corticosteroids prior to future infusions may be considered.

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: • Amyloid Related Imaging Abnormalities [see Warnings and Precautions (5.1)] • Hypersensitivity Reactions [see Warnings and Precautions (5.2)] • Infusion-Related Reactions [see Warnings and Precautions (5.3)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of LEQEMBI has been evaluated in 2090 patients who received at least one dose of LEQEMBI. In Studies 1 and 2 in patients with Alzheimer’s disease, 1059 patients received LEQEMBI 10 mg/kg every two weeks. Of these 1059 patients, 50% were female, 79% were White, 15% were Asian, 12% were of Hispanic or Latino ethnicity, and 2% were Black. The mean age at study entry was 72 years (range from 50 to 90 years).

In the combined double-blind, placebo-controlled period and long-term extension period of Studies 1 and 2, 1604 patients received LEQEMBI for at least 6 months, 1261 patients for at least 12 months, and 965 patients for 18 months.

In the double-blind, placebo-controlled period in Study 2, patients stopped study treatment because of an adverse reaction in 7% of patients treated with LEQEMBI, compared to 3% of patients on placebo.

In Study 2, the most common adverse reaction leading to discontinuation of LEQEMBI was ARIA-H microhemorrhages that led to discontinuation in 2% (15/898) of patients treated with

Adverse Reaction

1

LEQEMBI N=898 %

Placebo N=897 %

Infusion-related reactions

26

7

ARIA-H

14

8

ARIA-E

13

2

Headache

11

8

Superficial siderosis of central nervous system

6

3

Rash1

6

4

Nausea/Vomiting

6

4

Rash includes acne, erythema, infusion site rash, injection site rash, rash, rash erythematous, rash pruritic, skin reactions, and urticaria.

Less Common Adverse Reactions Atrial fibrillation occurred in 3% of patients treated with LEQEMBI compared to 2% in patients on placebo. In Study 1, lymphopenia or decreased lymphocyte count were reported in 4% of patients treated with LEQEMBI after the first dose, compared to less than 1% of patients on placebo [see Warnings and Precautions (5.3)]; lymphocytes were not measured after the first dose in Study 2.

8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate data on LEQEMBI use in pregnant women to evaluate for a drug associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

No animal studies have been conducted to assess the potential reproductive or developmental toxicity of LEQEMBI. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.

8.2 Lactation Risk Summary There are no data on the presence of lecanemab-irmb in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Published data from other monoclonal antibodies generally indicate low passage of monoclonal antibodies into human milk and limited systemic exposure in the breastfed infant. The effects of this limited exposure are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for LEQEMBI and any potential adverse effects on the breastfed infant from LEQEMBI or from the underlying maternal condition.

8.4 Pediatric Use Safety and effectiveness of LEQEMBI in pediatric patients have not been established.

8.5 Geriatric Use In Studies 1 and 2, the age of patients exposed to LEQEMBI 10 mg/kg every two weeks (n=1059) ranged from 50 to 90 years, with a mean age of 72 years; 81% were 65 years and older, and 39% were 75 years and older. No overall differences in safety or effectiveness of LEQEMBI have been observed between patients 65 years of age and older and younger adult patients.

17 PATIENT COUNSELING INFORMATION Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide).

Amyloid Related Imaging Abnormalities Inform patients that LEQEMBI may cause Amyloid Related Imaging Abnormalities or “ARIA”.

ARIA most commonly presents as a temporary swelling in areas of the brain that usually resolves over time. Some people may also have small spots of bleeding in or on the surface of the brain. Inform patients that most people with swelling in areas of the brain do not experience symptoms, however, some people may experience symptoms such as headache, confusion, dizziness, vision changes, nausea, aphasia, weakness, or seizure. Instruct patients to notify their healthcare provider if these symptoms occur. Inform patients that events of intracerebral hemorrhage greater than 1 cm in diameter have been reported infrequently in patients taking LEQEMBI, and that the use of anticoagulant or thrombolytic medications while taking LEQEMBI may increase the risk of bleeding in the brain. Notify patients that their healthcare provider will perform MRI scans to monitor for ARIA [see Warnings and Precautions (5.1)].

Inform patients that although ARIA can occur in any patient treated with LEQEMBI, there is an increased risk in patients who are ApoE ε4 homozygotes and that testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Inform patients that if testing is not performed, it cannot be determined if they are ApoE ε4 homozygotes and at a higher risk for ARIA. Patient Registry Advise patients that the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) is a voluntary provider-enrolled patient registry that collects information on treatments for Alzheimer’s disease, including LEQEMBI. Encourage patients to participate in the ALZ-NET registry [see Warnings and Precautions (5.1)].

Hypersensitivity Reactions Inform patients that hypersensitivity reactions, including angioedema and anaphylaxis have occurred in patients who were treated with LEQEMBI. Advise patients to seek immediate medical attention if they experience any symptoms of serious or severe hypersensitivity reactions [see Warnings and Precautions (5.2)].

Infusion-Related Reactions Advise patients of the potential risk of infusion-related reactions, which can include flu-like symptoms, nausea, vomiting, and changes in blood pressure, the majority of which occur with the first infusion [see Warnings and Precautions (5.3)].

Manufactured by: Eisai Inc. Nutley, NJ 07110 U.S. License No. 1862 LEQEMBI® is a registered trademark of Eisai R&D Management Co., Ltd. © 2023 Eisai Inc. and Biogen. All trademarks are the property of their respective owners.

Printed in USA/August 2023

LEQEMBI® is a registered trademark of Eisai R&D Management Co., Ltd. © 2023 Eisai Inc. and Biogen. All trademarks and company names are the property of their respective owners.

LEQE-US2792 09/2023

LEQE-US2713

08/2023

EXHIBIT HALL MAP In the Rivoli Ballroom Booth No. Company AbbVie, Inc. - Advanced Parkinson’s Disease 122 AbbVie, Inc. - Chronic Migraine & Movement Disorders 124/126 AbbVie, Inc. – Migraine and Chronic Migraine 118 Access TeleCare 223 Acorda Therapeutics Inc. 309 Alexion, AstraZeneca Rare Disease 110 Amylyx Pharmaceuticals 307 argenx 313 Baylor Scott & White Healthcare 206 Catalyst Pharmaceuticals 109 Central Maine Healthcare 214 CommonSpirit Health 115 CoxHealth 318 Eisai Inc. 301/303 Eli Lilly 116 IPSEN Biopharmaceuticals Inc. 320 KabaFusion 212 Kaiser Permanente/The Permanente Medical Groups 111 Mayo Clinic Laboratories 208/210 McKesson 319 NeuroNet GPO 108 NorthShore Edward Elmhurst Health 114 Octapharma 324 Physicians Practice Enhancement 225 Quest Diagnostics 219 RISE Healthcare Group 107 RosmanSearch, Inc. 305 Samacare 322 Sanofi 317 Sevaro Health, Inc 113 SK Life Science 315 Summa Health 311 Sutter Health 323 Takeda Pharmaceuticals 321 UCB, Inc 221 Wave Neuroscience 112 Westchester Medical Center Health Network 106 Wolters Kluwer AAN Booth Axon Registry AAN Booth BrainPac AAN Booth Memership/Career Center 120

AAN Booths

28 #AANFC

225

324

223

322

323

EXHIBITORS AbbVie, Inc. - Advanced Parkinson’s Disease

Access TeleCare

Booth 120

accesstelecare.com We start with the medicine. We start with our physicians. With our network of more than 600 specialists and subspecialists from some of the nation’s most esteemed healthcare systems and academic medical centers, every hospital in every community can give its patients worldclass care. We facilitate that care with our technology. Our telemedicine carts are designed by physicians who understand how powerful technology can be but also how it can obstruct and frustrate if not done well. And, we support that care by working with hospitals to make it financially sustainable.

abbvie.com At AbbVie, our commitment to preserve the personhood of those living with neurological disorders is unwavering. Every challenge in this uncharted territory makes us more determined and drives us harder to discover and deliver solutions for patients, care partners and clinicians. AbbVie’s Neuroscience portfolio consists of approved therapies and a robust pipeline in neurological disorders including Parkinson’s disease and others.

AbbVie, Inc. - Chronic Migraine & Movement Disorders abbvie.com AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas.

AbbVie, Inc. – Migraine and Chronic Migraine Booth 124/126 abbvie.com Bolstered by the Allergan neuroscience legacy, AbbVie is a committed leader in migraine with an almost 25-year history in migraine research.

Our current migraine treatments demonstrate our dedication to addressing the unmet needs of migraine and chronic migraine patients – and we continue to strive for science that makes a difference.

Acorda Therapeutics Inc. Booth 223 acorda.com Acorda Therapeutics is a biopharmaceutical company that markets two products, INBRIJA® (levodopa inhalation powder) and AMPYRA ® (dalfampridine) Extended Release Tablets.

Alexion, AstraZeneca Rare Disease Booth 309 alexion.com Alexion is a global biopharmaceutical company with the mission of transforming the lives of people affected by rare diseases by continuously innovating and creating meaningful value in all that we do. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

AAN.com/FCQuickLinks

29

EXHIBITORS

Booth 122

Booth 118

EXHIBITORS Amylyx Pharmaceuticals Booth 110 amylyx.com Amylyx is a Cambridge-based pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders. Guided by our core values, we incorporate unconventional approaches through strong partnerships with industry leaders, scientists, doctors and organizations. We work collaboratively across everything we do to positively impact the lives of patients and their families.

argenx

EXHIBITORS

Booth 307 argenx.com argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer. By translating immunology breakthroughs into innovative drug candidates, argenx is building a world-class portfolio of first-in-class antibodies in both early and late clinical-stages of development.

Axon Registry AAN Booth aan.com/practice/axon-registry The AAN’s Axon Registry is a FREE US member benefit that is designed to optimize your data to improve care. It’s a tool that collects, reports, and analyzes patient Electronic Health Record (EHR) data to show what you’re doing right and what can be improved. The Axon Registry also reduces your administrative burden, automatically collects quality improvement data, and simplifies reporting for proper reimbursement and Continuing Certification. Eligible physicians who sign up and meet the reporting requirements can utilize the Axon Registry to assist with reporting clinical quality data to the Merit-based Incentive Payment System (MIPS) – Fully integrated providers that use their dashboard for quality improvement have the opportunity to use the

30 #AANFC

Axon Registry as a Continuing Certification (CC) Part IV PIP Clinical Module activity and also waive up to eight credits of Part II Selfassessment.

Baylor Scott & White Healthcare Booth 313 bswhealth.com Baylor Scott & White Health is transforming healthcare for the Better, so that our patients and health plan members receive the high-value care they deserve when and where they need it. Our team of over 47,000 employees across more than 1,000 access points is committed to the wellbeing of every individual, family and community we serve. Through innovation, education and care delivery, we strive to provide an exceptional customer experience, while working to make healthcare more convenient and more affordable.

BrainPac AAN Booth aan.com/advocacy/brainpac BrainPAC is the political action committee (PAC) of the American Academy of Neurology, and the only federal political action committee in Washington, DC, that specifically represents the profession of neurology. It gives the AAN a strong voice on Capitol Hill and exists to support and help elect neurology-friendly candidates to the U.S. Congress. Personal contributions to BrainPAC help us advocate for AAN priorities.

BrainPAC is a nonpartisan PAC and contributes to both Democrats and Republicans who support our issues.

Information is accurate as of October 10, 2023, and is subject to change.

Exhibit Hall Passport Destination

Catalyst Pharmaceuticals

CommonSpirit Health

Booth 206

Booth 214

catalystpharma.com With exceptional patient focus, Catalyst is committed to developing and commercializing innovative first-in-class medicines that address rare neurological and epileptic diseases.

Catalyst’s U.S. commercial product portfolio consists of FIRDAPSE® (amifampridine) Tablets 10 mg, approved for the treatment of LambertEaton myasthenic syndrome (“LEMS”) for adults and children ages six to seventeen. In January 2023, Catalyst acquired the U.S. commercial rights of FYCOMPA® (perampanel) CIII, a prescription medicine approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures, and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older. Further, Canada’s national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

commonspirit.org CommonSpirit Health is a non-profit, Catholic health system dedicated to advancing health for all people. With approximately 150,000 employees and 25,000 physicians and advanced practice clinicians, CommonSpirit operates 139 hospitals and more than 1,000 care centers serving sites across 21 states.

Booth 109 cmhc.org Central Maine Healthcare (CMH) is an integrated healthcare delivery system serving 400,000 people living in central, western, and midcoast Maine. CMH’s hospital facilities include Central Maine Medical Center in Lewiston, Bridgton Hospital, and Rumford Hospital. CMH also supports Central Maine Medical Group, a primary and specialty care practice organization.

Whether seeing your primary care provider, a highly-qualified specialist within our healthcare network, or visiting one of our three hospital locations throughout Maine, be assured that with Central Maine Healthcare you’re always receiving accessible, comprehensive, world-class care.

Booth 115 coxhealth.com CoxHealth system includes six hospitals with over 80 clinics and 537 physicians serving 24 counties. Ferrell-Duncan Clinic, our multispecialty clinic physician group, offers 23 specialties.

Eisai Inc. Booth 318 us.eisai.com As the U.S. pharmaceutical subsidiary of Tokyobased Eisai Co., Ltd., we are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementiarelated diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at eisai.com/US and follow us on Twitter and LinkedIn.

Eli Lilly Booth 301/303 lilly.com Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded in 1876 by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission.

To learn more, visit lilly.com.

AAN.com/FCQuickLinks

31

EXHIBITORS

Central Maine Healthcare

CoxHealth

EXHIBITORS

EXHIBITORS IPSEN Biopharmaceuticals Inc.

Mayo Clinic Laboratories

Booth 116

mayocliniclabs.com Our laboratories, led by clinical neurologists, offer a highly specialized test menu that provides answers for everything from the simplest to the most complex cases. These neurologists are experts in their field and available seven days a week to help fellow physicians interpret each evaluation to provide clinically actionable answers, not just results.

ipsenus.com Ipsen is a global biopharmaceutical company focused on innovation and specialty care. At Ipsen, we develop and commercialize medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Disease. We work to provide hope for patients whose lives are challenged by difficult-to-treat diseases, including neurological disorders such as certain types of spasticity and cervical dystonia. Our people are driven by a passion to help patients and bring our mission to life every day. We are always ready to listen to—and learn from—patients. Every day, our more than 5,700 employees worldwide, including over 600 in North America, work diligently to improve the lives of patients around the world. For more information, please visit ipsenus.com.

KabaFusion Booth 320 kabafusion.com Speciality Pharmacy offering Home Infusion of IVIG/SCIG and acute therapies for infusion.

Kaiser Permanente/The Permanente Medical Groups Booth 212 physiciancareers-ncal.kaiserpermanente.org Kaiser Permanente is passionate in our commitment to improving the nation’s health care system. Through our leadership in the use of advanced technology, our creation of innovative solutions and our influence on health policy and reform efforts, we are shaping the future of health care both nationally and abroad.

32 #AANFC

Booth 111

McKesson Booth 208/210 mckesson.com McKesson helps neurology providers run profitable, independent businesses by clearing the path for them to focus on patient care. We offer an impactful portfolio of solutions that makes practice management more manageable by increasing efficiency, productivity, and profitability for specialty providers. Our Onmark Group Purchasing Organization (GPO) helps providers maximize their purchasing power, while our support services go above and beyond the essentials of pharmaceutical distribution. We take a highly-collaborative “all in” approach to understanding each practice’s unique needs. This tailored approach informs the business insights, strategies, and resources we offer, including regulatory guidance, advocacy, and full-service management options for physician-owned specialty practices. Intrafusion by McKesson is full-service infusion management that clears the path for independent, community-based specialty providers to care for their patients while growing a successful, high-quality infusion center. Our “all in” approach combined with proven results and a comprehensive portfolio of solutions ensure your infusion center operates productively, efficiently and profitably.

Information is accurate as of October 10, 2023, and is subject to change.

Exhibit Hall Passport Destination

Memership/Career Center

Octapharma

AAN Booth

Booth 114

careers.aan.com & aan.com/membership The Neurology Career Center is a world’s largest neurology-focused career resource. Stop by the booth to view available jobs, observe demos, pick-up a copy of the July Career Compass job guide and other gifts.

octapharmausa.com Largest privately owned plasma products manufacturer.

RISE Healthcare Group Booth 219

NeuroNet GPO Booth 319

NorthShore Edward Elmhurst Health Booth 108 eehealth.org NorthShore/Edward Elmhurst Health is ninehospital system with a broad footprint in the Chicagoland area. Our group provides coverage at two hospitals in the western suburbs. A fully integrated, healthcare delivery system with nine (9) hospitals and more than 2,400 affiliated physicians, including 975 members of the NorthShore University Medical Group with more than 140 practice locations. Our Neurosciences programs include a comprehensive stroke center with neurointerventional/endovascular services, a dedicated cardiac and neurocritical care units staffed by neurointensivists, and robust neuro-oncology and multidisciplinary neurology programs.

RosmanSearch, Inc. Booth 107 rosmansearch.com RosmanSearch is a Neurosurgery, Neurology and APP recruitment firm. We place quality providers with quality practices nationwide. We are the only search firm with dedicated teams specializing in neuroscience. Our mission is to be the best, the most expert, and the one that is known for quality—every time!

AAN.com/FCQuickLinks

33

EXHIBITORS

neuronetgpo.com NeuroNet GPO is a group purchasing organization focused on serving the needs of outpatient clinical practices and their ancillary services. GPO members partner with practices nationwide to leverage purchase power, resulting in discounted pricing on drugs and supplies. Members also gain access to valuable information and resources, which helps maximize operating performance.

risehealthcaregroup.com The booth will display a number of exoskeletons that are used in a physical therapy setting. There will be the full lower body HAL (Hybrid Assistive Limb), and the Single Limb for upper and lower extremity. There will be personnel at the booth that will be demonstrating the use of the devices on themselves, and you will see the HAL device walking around in the booth during the demonstrations. There will be active monitors displaying the exoskeletons being used in the physical therapy setting. Along with these short clips, there will be displayed short testimonials from patients, as well as our latest research projects using the technology.

EXHIBITORS pharmaceutical organization. SK life science has two CNS products in late stage development.

Samacare Booth 305 samacare.com SamaCare helps practices streamline prior authorizations for physician-administered medications, across payers, through a guided portal. SamaCare’s dedicated team of experts works with specialty providers across the country to ensure patients receive timely access to care. SamaCare is available free to specialty practices that meet certain criteria thanks to partnerships with pharmaceutical market access and reimbursement organizations.

Summa Health Booth 315 summahealth.org Summa Health – headquartered in Akron, Ohio – is one of the largest integrated Healthcare Delivery Systems in the state. With 2 hospitals and 20+ health centers, Summa Health provides access to care throughout the region.

Sutter Health Booth 311

Sanofi

EXHIBITORS

Booth 322 sanofi.com/en/your-health/specialty-care Sanofi’s Specialty Care business is committed to meeting significant unmet medical needs. By partnering with scientific, healthcare and patient communities, we continue to build on our legacy of collaboration and inspiration, understanding and experience, empathy and knowledge to drive the development of potential new therapies and to help change what it means to live with a neurological disease.

Sevaro Health, Inc Booth 317 sevaro.com Sevaro provides telestroke, teleneurology, and EEG services to hospitals and health systems.

SK Life Science Booth 113

sutterhealth.org Sutter Health is one of the nation’s leading community-based, not-for-profit health care networks of hospitals, physician organizations, home health and hospice agencies and other health care services. We share our expertise and resources to advance the quality of care in the communities we serve. We offer our employees an environment that is conducive to professional performance. Our facilities and services are located in large, urban cities and small, rural communities from the Pacific Coast to the Sierra Foothills and from the Oregon border to the San Joaquin Valley. They are situated near major West Coast attractions: San Francisco, Sacramento, the snowy mountains of the Sierra Nevada and Lake Tahoe, the Napa Valley, Yosemite Valley and the coastal redwoods. We even have an affiliate in Hawaii. Join us and be part of a dedicated group of professionals with the resources, training and expertise to provide the most advanced and highest quality health care.

SKLifeScienceInc.com SK life science, a subsidiary of SK biopharmaceuticals, has focused its efforts on research and development in CNS disorders since 1993. We are a part of SK Group, a global conglomerate and the second largest company in Korea. In the US, we are transitioning from a clinical-stage company to a fully-integrated

34 #AANFC

Information is accurate as of October 10, 2023, and is subject to change.

Exhibit Hall Passport Destination

UCB, Inc

Wolters Kluwer

Booth 321

Booth 106

ucb.com UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. Follow us on Twitter: @UCB_news.

lww.com Wolters Kluwer Health is a global provider of information, business intelligence and pointof-care solutions for the healthcare industry .

Brands include Lippincott Williams & Wilkins, a leading international publisher of medical books, electronic media and journals and the official publisher of American Academy of Neurology.

We proudly offer specialized publications and software for physicians, nurses, students and clinicians. Please visit our booth to browse our comprehensive product line.

Wave Neuroscience Booth 221

EXHIBITORS

waveneuro.com Wave Neuroscience is elevating brain healthcare for your practice with a turn-key platform that brings precision, personalized care to all of your patients. Wave’s approach pinpoints abnormal default mode network activity using a rapid 10-minute EEG recording. This data is used to generate an individualized brain health report & frequency and location-specific protocol for Transcranial Magnetic Stimulation therapy.

Westchester Medical Center Health Network Booth 112 wmchealthjobs.org The Westchester Medical Center Health Network (WMCHealth) is a 1,900-bed healthcare system headquartered in Valhalla, New York, with ten hospitals on eight campuses spanning 6,200 square miles of the Hudson Valley.

WMCHealth employs more than 12,000 people and has nearly 3,000 attending physicians. From Level 1, Level 2, and Pediatric Trauma Centers, the region’s only acute care children’s hospital, an academic medical center, several community hospitals, dozens of specialized institutes and centers, skilled nursing, assisted living facilities, homecare services, and one of the largest mental health systems in New York State, today WMCHealth is the pre-eminent provider of integrated healthcare in the Hudson Valley.

AAN.com/FCQuickLinks

35

CONFERENCE GUIDELINES & POLICIES The following are guidelines for AAN conferences. Unless specified, these guidelines apply to all AAN conference formats. In addition to the below guidelines, participation in an in-person or online AAN meeting is subject to AAN’s Privacy Policy (AAN.com/PrivacyPolicy). All individuals engaged in any in-person or online meeting are subject to the AAN.com Code of Conduct (AAN.com/Conduct), unless otherwise specifically noted. Use of the website and online program site(s) is subject to AAN’s Terms of Use (AAN.com/TermsofUse). These conference policies are subject to change without notice, at AAN’s discretion. Any changes will be reflected on AAN.com/ConfGuidelines.

ACCME Accreditation The American Academy of Neurology Institute (AANI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation The American Academy of Neurology Institute (AANI), a subsidiary of the AAN, designates this live activity for a maximum of (*) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. *See individual program descriptions for the maximum number of credits per program.

ABPN Statement The American Board of Psychiatry and Neurology has reviewed the relevant AAN conference and has approved the program as a part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of continuing certification.

Commitment to Inclusion, Diversity, Equity, Anti-racism, and Social Justice (IDEAS) The AAN is committed to intentional actions to be a fully inclusive, deliberately diverse, and anti-racist organization that respects and values our membership, our staff, and the communities we serve. We actively promote equity and social justice in neurology and the neurosciences. As part of this commitment, the AAN is working to ensure we provide a conference environment and educational programming that is fully inclusive, deliberately diverse, and anti-racist. If you have questions about these efforts, identify areas for improvement, or have concerns regarding attendee or staff behavior, please contact Member Services at (800) 879-1960, memberservices@aan.com, or conference staff.

36 #AANFC

Professional Conduct and Anti-harassment The AAN expects all meeting participants, including attendees, members, speakers, staff, contractors, vendors, and exhibitors, to behave respectfully, responsibly, and professionally towards each other, and to abide by the AAN’s Meetings Anti-Harassment Policy during the conference. The AAN is committed to providing a conference environment that is free from all forms of discrimination and harassment. Violations of this policy may be reported to Member Services at (800) 879-1960, memberservices@aan.com, or to conference staff.

Authorization for Use of Image, Name, and Other Likeness By attending the AAN meeting or logging into the meeting’s website(s) or application(s) and engaging in any activities or interactive features, you agree that AAN/AAN and/or third parties authorized by AAN/AANI may photograph or record your likeness, image, name, voice, and/or words, and may publish, display, reproduce, copy, and distribute your likeness, image, name, voice, and/or words for promotional, educational, or membership activities worldwide in all forms of media now known or later developed, including but not limited to advertising, training, websites, presentations, and marketing materials. You further acknowledge that AAN/AAN and/or third parties authorized by AAN/AAN have the right, but not the obligation, to identify you in connection with such media by name and/or affiliation. No royalties will be payable in connection with this authorization or these uses.

Social Media The American Academy of Neurology (AAN) encourages all AAN conference attendees to share their experience on social media using the official conference hashtag (#AANFC).

When doing so, please adhere to the following AAN Meetings Social Media Policies: • Photography and screenshots of presentations are permitted for personal use only.

Photography or screenshots for commercial use are strictly prohibited.* • Do not disrupt fellow attendees.

• Do not post any information or other material protected by copyright without the permission of the copyright owner.

• Do not post confidential or identifiable patient information.

• Do not post any material that is defamatory, abusive, profane, threatening, offensive, illegal, or violates any third party’s rights.

• Videography, including live streaming, is strictly prohibited regardless of intended use.

• Usage of the AAN logo or an AAN conference logo on social media is prohibited.

The AAN has the right to ask any AAN conference attendee to remove a social post or to stop taking photos or recording video at any time.

AAN.com/FCQuickLinks

37

UPCOMING EVENTS

Annual Meeting

April 13–18, 2024 Denver and Online Register Now: AAN.com/AM

Denver and Online • April 13–18

Autoimmune Minneapolis andNeurology Online

July 19–20, 2024 Atlanta and Online October 25–27, 2024 Las Vegas and Online